Literature DB >> 283259

Photoradiation in the treatment of recurrent breast carcinoma.

T J Dougherty, G Lawrence, J H Kaufman, D Boyle, K R Weishaupt, A Goldfarb.   

Abstract

Photoradiation, with the use of hematoporphyrin derivative (Hpd) activated by visible light in the red region of the spectrum, was an effective treatment for controlling local and regional chest wall recurrences of breast carcinoma. With sufficient time between iv injection of the drug and local activation with red light, cutaneous and subcutaneous masses were treated effectively without undue damage to overlying and adjacent skin. This high therapeutic ratio resulted from the ability to Hpd to accumulate and/or to be retained to a higher degree in malignant tissue than in many normal tissues. This technique can be used as a primary treatment or upon tumor recurrence following conventional modalities such as surgery, chemotherapy, and radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 283259

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  31 in total

1.  Photodynamic therapy for cancer.

Authors:  A M Abulafi; N S Williams
Journal:  BMJ       Date:  1992-03-07

Review 2.  A review of progress in clinical photodynamic therapy.

Authors:  Z Huang
Journal:  Technol Cancer Res Treat       Date:  2005-06

3.  Photodynamic therapy of esophageal carcinoma.

Authors:  T Okunaka; H Kato; C Conaka; H Yamamoto; A Bonaminio; M L Eckhauser
Journal:  Surg Endosc       Date:  1990       Impact factor: 4.584

4.  Trans-spectral organic dye laser photocoagulation.

Authors:  F A L'Esperance
Journal:  Trans Am Ophthalmol Soc       Date:  1985

5.  Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2004-12       Impact factor: 3.631

6.  Advanced smart-photosensitizers for more effective cancer treatment.

Authors:  Wooram Park; Soojeong Cho; Jieun Han; Heejun Shin; Kun Na; Byeongdu Lee; Dong-Hyun Kim
Journal:  Biomater Sci       Date:  2017-12-19       Impact factor: 6.843

7.  Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells.

Authors:  J K Steele; D Liu; A T Stammers; S Whitney; J G Levy
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 8.  Current use of lasers in pulmonary disease.

Authors:  M R Hetzel
Journal:  World J Surg       Date:  1983-11       Impact factor: 3.352

9.  Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity.

Authors:  R M Böhmer; K Hoffmann; G Morstyn
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Selective incorporation of 111In-labeled PHOTOFRIN by glioma tissue in vivo.

Authors:  H T Whelan; L H Kras; K Ozker; D Bajic; M H Schmidt; Y Liu; L A Trembath; F Uzum; G A Meyer; A D Segura
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.